Session V Open Forum
Chairman Professor V Wynn Dr A N Howard (Cambridge) asked Professor Nikkila what he considered to be the mechanism of action of gemfibrozil on serum triglycerides.
Professor E A Nikkila (Helsinki) said that even though they had heard several good presentations on the effect of gemfibrozil on lipolysis in adipose tissue he still did not believe that the changes in adipose tissue in patients receiving gemfibrozil were understood. Drug concentrations used in rat and human adipose tissue were high compared to pharmacological concentrations. He therefore agreed with Professor Carlson that there was no definite evidence of gemfibrozil acting through a nicotinic acid-like pathway. This was true in spite of the data presented by Dr Kissebah, which showed that there was a reduction of FFA turnover. It was therefore appropriate to consider the action of the drug on the liver, and the data of Dr McLean Baird showing a reduction of bile acid output, though perhaps not directly related to the action of the drug, did indicate an action on the liver and on the synthesis of lipids, particularly lipoproteins. A correlation was known to exist in the untreated state between VLDL triglycerides and the output of bile acids, which suggested to him an increased production, on the one hand of bile acids going to the bile, and on the other of VLDL particles going to the blood. Although there was no firm evidence that the drug reduced both these pathways, he believed that this subject should be further investigated, because there was good evidence that clofibrate and gemfibrozil reduced the production of VLDL triglycerides. Finally, it was necessary to consider the action of the drug in the removal phase. He did not wish to repeat what had been said already, but there seemed a distinct possibility that the drug might act perhaps 25 % on removal and 75 % on the production of triglycerides.
Dr P Ghosh (Cambridge) asked how normal lipid levels were defined. In 1958 in Davidson's 'Principles and Practice of Medicine' the upper limit of normal cholesterol was quoted as 300 mg/100 ml. It changed to 260 mg/l00 ml in the 1972 edition, and Fredrickson's own estimates of normal values had also fallen in recent years. This figure also differed with geographical regions. For the Masai tribe, for example, it might be about 135 mg/100 ml.
Professor Nikkila agreed that there was an enormous variation in what was considered the upper limit of normal for LDL cholesterol or total cholesterol even in affluent countries. Limits that were once given to a normal population by workers like Fredrickson did not now apply either in Britain or in Scandinavia, and 25% of the Swedish or Finnish population had values over these limits.
Professor V Wynn (Chairman) said that he would ask Professor Carlson to discuss this aspect later.
Before that, however, he wished to make several observations on the presentations given during the conference. Not one speaker had defined the term 'hyperlipidaemia', and consequently they had been talking about a mixed sample of patients. This was perhaps inevitable since the hyperlipidcemias were an extremely complex group of conditions. Patients did not exemplify the same hyperlipidcmic abnormality consistently from week to week, and a whole variety of conditions could arise which resulted in a change in their lipid pattern.
This was not a very satisfactory situation, either for the drug manufacturer trying to produce a lipid lowering agent or for the investigator who was trying to compare his results with those of other investigators around the world. He suggested that there should be greater attention to the categorization of the lipid abnormalities which were under investigation.
In concentrating largely on type IV and type V hyperlipidwmia, investigators might have lost sight of the earlier work in this field where hyperlipidwmias were described essentially in terms of endogenous or exogenous hypertriglyceridcemia.
In future, before describing plasma triglyceride and cholesterol levels, he believed sera should be subjected to a preliminary chylomicron spin since it could not be assumed that the patient was in a fasting condition. Nor could it be assumed, in hypertriglyceridmmic individuals, that fasting levels would always exemplify the problem of endogenous hypertriglyceridcmia. It was not uncommon to find individuals who after a onenight's exposure to even reasonable quantities of alcohol would have serum triglyceride values up to 1000 mg/100 ml. In regarding such an example as a case of simple endogenous hypertriglyceridamia (so-called type IV) the doctor would get very different results than if he subjected the serum to chylomicron spin, or preferably sent the patient away with instructions to abstain from alcohol.
It was surprising that none of the presenters accurately defined the status of their patients in terms of possible secondary mechanisms for hypertriglyceridewmia. He believed that every patient being so investigated must have the minimum following investigations: thyroid status, including TSH measurements and possibly TRH studies; liver function tests, including the more specific function tests such as BSP excretion and those that suggest enzyme induction perhaps by alcohol, such as GGTP estimations; renal function studies; and so forth. Every patient, whether hypertriglyceridmmic or hypercholesterolwmic, should also have a glucose tolerance test. A substantial number of patients were referred to him with so-called primary or acquired hypercholesterolemia who in fact had undiagnosed clinical or mild subclinical diabetes. Such individuals responded quite differently to drug treatment than did 'those who had normal glucose tolerance.
As to the methodology of lipoprotein analysis, there were physical methods such as ultracentrifugation, analytical or preparative, chemical methods based on precipitation techniques, and immunological methods based on radioimmunoassay. These approaches measured different components of the lipoprotein. Since the components were known to change, it was unreasonable to expect exact correlations between one method and another.
Perhaps the most unsatisfactory aspects in the epidemiological study of lipid abnormalities were the actual techniques involved. Cholesterol determinations showed a particular lack of precision. The older methods based on ferric chloride were very non-specific although they were simple. More recent methods based on the Liebermann-Burchard reagent and fluorimetry gave greater precision. GLC methods were good, and now specific enzyme methods existed. But all gave different results. Serum cholesterol values could differ by 40 mg/100 ml depending on whether a ferric chloride or a GLC method was used. Such a variation was unacceptable today. In addition, preparation of the patient was important. Although all patients were fasting, it was possible to induce a 14% variation in serum cholesterol within 15 min simply by changing the patient's posture from upright to horizontal. In patients with abnormal serum protein levels or with any abnormality in capillary permeability, these variations could be greater. He had seen variations of up to 30% in serum cholesterol due to posture, and the same applied to triglycerides.
The efforts of Professor Carlson and others had ensured that methods of triglyceride determination were much more satisfactory. Apart from his initial criticism of the lack of prior preparation of the sample by chylomicron spinning, he thought that the triglyceride methodology throughout the world was now of a high and uniform standard.
Professor L A Carlson (Stockholm) pursued Dr
Ghosh's question about 'normal' lipoprotein levels. For the statistician or the epidemiologist the definition was comparatively simple. For the clinician, however, the question was not so much 'what is normal?' as 'what shall I treat?' In the clinical situation several factors entered the picture and he could well imagine the possibility of treating a patient with clinical manifestations of atherosclerosis who had a cholesterol level as low as 200 mg/100 ml if he also had other severe risk factors.
Attempts were made to simplify the problem by referring, for example, to the upper 90 percentile of the population. In clinical practice the doctor was sometimes forced to talk of hyperlipidwmia or type IV hyperlipoproteinmmia simply to communicate the fact that this patient had a VLDL problem. The complexity was however increased by, for example, the relation between HDL and LDL lipoproteins. The sex of the individual and the cost-benefit of treatment must also be considered. But he too was unhappy with the imprecision of the typing systems, particularly those involving moderate types of hyperlipoproteinx,mia.
Professor B Lewis (London) said that the Lipid Research Clinic study in the United States was giving new ideas on what the range of serum lipid levels really was in that country. It was clear that the values given by Fredrickson in 1967 were not descriptive of the United States as a whole. Lipid Research Clinics were now reporting for the 95th percentile serum triglyceride levels as high as 3.0 mmol/l, which was much higher than values which had hitherto been accepted as representative of apparently healthy people.
In trying to define 'desirable' as opposed to statistically 'normal' lipid levels, it was necessary, on the one hand, to look at values present in coronary immune populations such as the Japanese, and also at levels in animals with experimental atherosclerosis in which attempts were being made to induce regression. In these circum-stances cholesterol levels were in the order of 4-5 mmol/l. If these considerations were valid, then those attempting to develop hypolipidwmic drugs would have to be more ambitious than they currently were. It might be necessary to develop drugs which would produce strikingly low levels rather than merely seeking to attain the 95th percentile cut-off points.
As to methodology, provided serum cholesterol was measured on an extract of serum, the type of colorimetric or fluorimetric procedure used might not make a great difference. The hazard lay in performing direct analyses on serum in which a large number of non-specific chromogens might interfere. Comparisons between colorimetry and enzyme measurements of cholesterol suggested that extraction methods such as the Technicon N24a or the Auto Analyzer II method overestimated cholesterol by about 8 mg, a consistent slight overestimate due presumably to material other than cholesterol contributing to the colour. The enzyme method was elegant and quick and could be easily automated. However, it was substantially more expensive than colorimetry and would probably not replace colorimetric methods until the price was reduced. He had little comment on triglyceride methods. Fluorimetric and colorimetric methods, especially if automated, produced reproducible and accurate results.
It was certainly necessary to characterize patients by means other than the simple concentration of cholesterol and triglyceride in plasma, and the approach of Fredrickson, Levy and Lees had been a bold step forward in providing a framework to discuss such problems. It had now been modified in various ways. It was recognized that within families in which the index patients showed one lipoprotein abnormality, other close relatives might show another pattern. It did not therefore define genetically homogeneous entities. Within a given lipoprotein type such as Ila, there were different modes of inheritance, and different mechanisms by which the abnormality was produced. Lipoprotein analysis was therefore a necessary step, but by no means a final one.
Lipoprotein 'typing' by inspecting stored serum was a method which was difficult to standardize, but was nonetheless very informative in distinguishing between endogenous and exogenous hypertriglyceridcmia. The method was inexpensive and adequate for treating many patients. Electrophoresis was also required and of particular value in distinguishing between hypercholesterolemia of moderate degree caused by raised betaor alpha-lipoprotein levels. Primary and secondary hyperalpha-lipoproteinamia was probably not as rare as was once thought, and was a variation from normal which did not require therapy.
Lipoprotein quantification was also important and until recently ultracentrifugation was necessary to achieve quantitative separation. As described by Dr Janus, precipitation methods such as that by Mr Ononogbu make quantitative separation of lipoproteins far easier, permitting measurement of their lipid components. It had also become increasingly clear that lipoprotein composition was far from constant. The HDL and LDL chemistry in patients treated with gemfibrozil was clearly different from that in patients before they were treated. The hyperlipideamia might result from qualitative as well as quantitative changes in lipoproteins.
Finally, a new phase in investigating patients with lipid abnormalities must be the function test. This was exactly analogous to investigating abnormalities in carbohydrate metabolism, where the doctor proceeded from measurement of concentration to tests of function. This was the trend in endocrinology.
One such test which he had used in relation to gemfibrozil was the i.v. fat tolerance test, which would broadly distinguish between individuals with hypertriglyceridxemia caused by impaired catabolism and those with overproduction, a primary division in terms of mechanism.
There was some debate on the subject of performing glucose tolerance tests in all patients. There was a problem in defining those individuals who lay in the 'grey zone' between mild glucose intolerance and endogenous hypertriglyceridaemia. Recent family studies from Seattle indicated that where these two abnormalities coexisted it was usually the result of separate inheritance of hypertriglyceridwmia and diabetes, owing to two common genes. Another view postulated the existence of a syndrome in which hypertriglyceridcmia, glucose intolerance, hyperinsulinism and obesity were all a part. As yet, neither view was established.
Dr A H Kissebah (London) said it was clear that some patients responded to a drug (whatever it was) and some did not. The distinction between them might be found in kinetic studies of production and clearance.
His own investigations led to the conclusion that increased production would ultimately lead to impaired clearance, because saturating the clearance system would give an apparent clearance defect. Patients in this situation would not respond to such drugs as clofibrate or gemfibrozil, or to any drug which acted on the liver. Such patients would respond well to reduction of weight and dietary restriction, which would ultimately lower serum triglycerides, mainly chylomicrons and some of the VLDL, and ultimately bring the patient back to a normal equilibrium where the circulating system could cope with increased production and then perhaps permit some observable drug effect.
Thus, by defining the kinetics of the patient, it might be possible to prescribe the ideal treatment. However, the intralipid test might not give the required information because all patients would have an impaired K2 if their serum triglycerides were above a certain level, in which situation the test by definition became an investigation of K1. However, if it were possible to reduce the serum triglycerides in such a patient by dietary restriction over a long period, K2 investigations might then be helpful in determining this defect. In this context it might be instructive to study the KM, the plasma half concentration at which the patient started to saturate. But such studies were not possible in patients with marked hypertriglyceridmmia, and they required isotopic techniques which were not easy to apply to every patient.
Professor Wynn said that there was one exception to the suggestion that every patient with raised triglyceride production would at some stage exceed his clearance maximum and show a clearance defect. There were some drugs which might increase the rate of serum clearance. Progestagens and anabolic steroids had direct effects on KM and the clearing mechanism. There were two possibilities to consider: the combination of a hypolipidemic drug such as gemfibrozil with a drug specifically designed to increase clearance, or the patient with apparently normal triglyceride values who might have a grossly elevated triglyceride production rate because of this specific effect on KM. This latter pattern was seen, for example, in individuals given alkylated anabolic steroids or progestagens, and to some extent in women on oral contraceptives. Dr D J Galton (London) asked how urgently the panel felt the need for a drug that lowered blood triglycerides. Certainly hypertriglyceridwmia was a very prevalent condition and might be a risk factor for arterial disease, but it was an environmentally responsive parameter unlike hypertension, for example, which did need drug treatment. The majority of hypertriglycerideemic patients could be treated by restriction of diet or alcohol intake. He therefore asked whether the panel felt that there was an urgent need for a hypotriglyceridoemic drug, and if one existed whether they would treat all of their hypertriglyceridcemic patients with it.
Professor Lewis said that treatment of hyperlipidwmia was firstly by attempting to deal with underlying causes such as alcohol, where this could be modified, and secondly by dietary modification. Nonetheless, there were a substantial minority of patients who did not respond adequately to these approaches. It was for this large minority that drug therapy was appropriate. Several years ago he had calculated that 25% of patients attending the Lipid Clinic at the Hammersmith Hospital required long-term drug therapy. In addition, if the aim was to lower lipid levels to a cholesterol level of 180-200 mg/100 ml (a goal of therapy, if one seldom attainable), then the need for pharmacological agents would increase.
Professor Carlson agreed and indicated the urgent need to understand the mechanisms of hyperlipidxmia in order to develop effective drugs. It had become clear from this and other meetings that animal models were extremely bad as screens for these drugs as long as the underlying pathophysiology remained unknown. Once the process was understood, allowing the development of drugs which reduced hyperlipidcmia to normal levels, many doctors would not hesitate to treat all the patients they saw with such a compound.
Professor Wynn referred further to the group of patients who did not normalize their lipid values when their obesity, diabetes, oral contraceptive and alcohol usage had all been corrected. He noted the well-established correlation between cholesterol and triglyceride production rates, and it seemed important to lower triglycerides in the hope of reducing actual LDL synthesis. Professor Lewis had shown the conversion of VLDL to LDL. This was a phenomenon which also took place at the endothelial surface, and there seemed to be evidence that this might be a reason for the increased atherogenic risk of individuals having relatively low plasma cholesterol but high triglyceride levels. Apparently, increased production of LDL in the patient, irrespective of low cholesterol levels, was a possible mechanism of the atherogenic effect, an effect which it was hoped to influence by lowering triglycerides.
Professor Lewis confirmed that LDL concentrations seemed independent of reduction in VLDL levels. The little kinetic evidence available suggested, rather surprisingly, that VLDL triglyceride concentrations might have an unexplained influence on the rate of catabolism of LDL, rather than its production. This reciprocal relationship between the concentration of VLDL and LDL could not be explained in terms of production of LDL from VLDL, but it seemed more clearly related to the catabolic rate of LDL.
The justification for treating raised VLDL levels must be based on a consideration of whether they were intrinsically atherogenic, a question which was still controversial. However, there was evidence from a number of sources that endogenous hypertriglyceridwmia, whether because of the triglyceride component of VLDL or not, was predictive of ischkmic heart disease.
Dr Kissebah said that in 9 patients whom they had studied and who had endogenous hypertriglyceridaemia, the conversion of VLDL to LDL was increased. This effect, surprisingly, was associated with low levels of LDL which, as Professor Lewis had said, suggested a high catabolic rate to maintain these molecules at a low concentration. The significance of this high catabolic rate had been discussed by Steinberg who had shown that removal of the liver did not influence the catabolic rate of LDL. Thus catabolism of LDL did not occur in the liver, but primarily in the periphery, and most likely in smooth muscle. Steinberg's view was that a high turnover of LDL might carry cholesterol into smooth muscle, subsequently leaving it behind where it acted as a cause of atherogenicity in type IV patients who had no obvious increase in LDL.
Professor Wynn asked speakers to comment on the relationship, as it was currently understood, between accelerated development of atherosclerosis and abnormality in serum triglyceride values.
Professor Lewis said that case-control studies indicated that endogenous hypertriglyceridaemia was, in most investigations, the commonest lipid abnormality in patients with ischemic heart disease and peripheral atherosclerosis. Such observations led to the prospective studies of Carlson and others, indicating that individuals with triglyceride levels in the upper quintile of the population were approximately twice as likely to develop ischmemic heart disease in the next 10 years as individuals in the remainder of the population. Hypertriglyceridamia, therefore, appeared to be a risk factor.
There was much current debate about whether this risk factor was 'independent' or whether the predictive value of a high triglyceride level was a consequence of the fact that triglyceride and cholesterol levels were weakly but positively correlated, and that a high triglyceride level was therefore also predictive of a high cholesterol level. Some workers have published evidence that hypertriglyceridwmia is not an independent risk factor. These results were obtained by the mathematical device of multivariate analysis in which the cholesterol level was effectively held constant in an attempt to establish whether knowledge of triglyceride levels gave any additional information beyond that provided by the cholesterol level. In his view, attempts to separate cholesterol and triglyceride mathematically, when they were so closely linked biologically as to be consistently present in the circulating lipoproteins, were open to question.
Unfortunately, there were no prospective studies of VLDL concentration to answer the critical question of whether raised levels of VLDL (either by virtue of its triglyceride content or by virtue of its substantial cholesterol component) conferred a risk of coron'ary disease. It was possible that VLDL was atherogenic by virtue of its cholesterol content, even though its concentration in plasma was determined by abnormalities of triglyceride metabolism. Professor Carlson's work threw light on this question, as did his own data which indicated that patients with various forms of primary hyperlipoproteinemia including type IV developed coronary disease at a younger age than normolipidemic patients who did not have the condition. This was true not only for patients with raised betalipoprotein levels, but also for those with raised prebeta-lipoprotein (that is raised VLDL) levels and normal LDL levels. There was, therefore, good reason to believe that accelerated atherogenesis followed the presence of a high VLDL concentration.
Professor Carlson said that recent findings had shown that not only beta-lipoproteins (LDL) but also very low density lipoproteins and particularly those of intermediate size were readily taken up by smooth muscle cells and sometimes even more readily than was the LDL.
As to clinical studies, he felt there was as much evidence for the role of VLDL, and particularly elevated VLDL levels in atherogenesis as for LDL, except for the one condition of very severe familial forms of hyper-low density lipoproteinaemia. Here the situation was not similar to that with VLDL, but these were very rare conditions. The most common lipoprotein abnormalities in ischaemic vascular disease, in his view, were certainly those involving VLDL with or without simultaneous involvement of LDL. Dr Howard, commenting on the papers of Dr Maxwell and Dr Creger, said that the structureactivity relationships for effect on triglycerides and cholesterol seemed quite distinct. The approach had been empirical and he wondered whether this might change now that more was known about these compounds and the way that they worked in man. The use of animal models had already been discussed, together with their Dr Kissebah said that type Ila patients differed shortcomings. However, he wondered whether it from type IV. As Professor Lewis had said, the had been possible to identify those parts of the turnover, that is the production, of VLDL seemed molecule which were essential for lowering tri-to be normal, and one would not expect to see glyceride levels and those which were essential for any change in VLDL levels from a drug which lowering cholesterol levels.
inhibited their production. These patients usually suffered from an impaired clearance of LDL, the Dr R E Maxwell (Ann Arbor) said that their cholesterol carrier, and if there was an effect it approach was necessarily empirical because they would be by a completely different mechanism, the had to select from thousands of compounds those degradation of LDL cholesterol or LDL itself. which were most potent by whatever end-point This would not be at all similar to the mechanism was being measured. The range of compounds seen in type IV patients. with potencies between say 50% and 70% were reported back to the chemist who then decided Dr Maxwell said that in animals eating normal which of the compounds he could select from the diets variations in response were seen, such that a practical standpoint of availability of inter-reported reduction of say 700% might not be mediates and methods of synthesis. Their significantly different from 50 %. selection based on these criteria were usually as In animals made hyperlipidcmic, a tremendous good as those that the pharmacologist could make variation in response was observed. This was why on the basis of small observed differences in most investigators had little success of studying potency.
the effects of drugs in animals made hyper-In contrast to their own necessarily empirical lipidamic by dietary or other means. He had approach, he hoped that studies of mechanism of been interested in Dr Manninen's report of action would be carried out by members of the hypoxia as a model with which these drugs could academic community who were perhaps in a be shown to be effective. However, the relevance better position to do so, although, of course, they of this model to dietary or metabolic hyperperformed some studies to eliminate the possi-lipidemia was not obvious. bility of grossly undesirable metabolic effects. Dr Creger had shown some compounds with a Professor Wynn in conclusion thanked Parke, more potent effect in reducing cholesterol levels, Davis & Co. for organizing a symposium covering but unfortunately they had proved to be too many important and fundamental aspects of lipid toxic to be acceptable. It seemed that those metabolism. He thought it showed a remarkable compounds most effective in reducing cholesterol attitude on the part of the Company that they levels were also the most toxic, a finding the were prepared to put a tremendous effort into significance of which might itself be worthy of this work and to support research in so many study.
countries. Everyone appreciated their efforts to create the drug, to promote its toxicological study Dr J A L Gorringe (Pontypool) commented on and to have it passed by the various regulating the fact that some patients were totally non-agencies to be available for clinical investigation responsive to a particular drug. Of a relatively throughout the world. He hoped very much that large group of type Ila patients in Finland whose the drug proved to be as successful as he believed problem was hypercholesterolhmia in the pres-present indications suggested that it should be. ence of relatively normal triglyceride levels, approximately 10% were totally non-responsive Dr Gorringe, in reply, thanked the Chairmen for to either clofibrate or gemfibrozil. He asked Dr their exemplary record of timekeeping and the Kissebah to suggest an explanation. speakers for the enormous amount of trouble they He also asked Dr Maxwell whether the pheno-had taken to assemble and present their data in menon of complete drug unresponsiveness was such an excellent manner. He wished -them to observed in individual animals as it was in know that the Company which developed the drug individual people. was extremely grateful to them.
